USPH · XBRL financial data

U S Physical Therapy financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (USPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	150	155*	156	167	168	180*	184	197	197	203*	198	214
Revenue from contracts with customers	150	155*	156	167	168	180*	184	197	197	203*	198	214
Gross profit	28	—	28	34	29	—	31	42	37	—	33	42
Selling, general and administrative	12	14*	14	14	14	16*	16	17	17	18*	18	19
Operating income (loss)	16	(1)*	14	20	15	15*	20	25	25	17*	12	22
Interest income	2	2*	2	1	1	0*	0	0	0	0*	0	0
Other income (expense)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Income tax expense (benefit)	4	1*	3	3	3	6*	4	5	5	6*	2	4
Net income (loss)	9	1*	8	8	7	9*	10	12	13	4*	5	10
Earnings per share, basic USD per share	0.51	—	0.46	0.47	0.39	0.61*	0.80	0.58	0.48	—	(0.12)	0.25
Earnings per share, diluted USD per share	0.51	—	0.46	0.47	0.39	0.61*	0.80	0.58	0.48	—	(0.12)	0.25
Weighted average shares, basic millions of shares	15	15*	15	15	15	15*	15	15	15	15*	15	15
Weighted average shares, diluted millions of shares	15	15*	15	15	15	15*	15	15	15	15*	15	15

Fiscal quarters (USPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	148	153	132	113	117	41	39	34	31	36	28	25
Accounts receivable	53	52	55	55	57	59	65	66	68	64	69	70
Total current assets	228	233	221	202	205	138	145	141	138	140	139	140
Property and equipment, net	26	26	26	26	27	32	33	32	34	36	39	40
Right-of-use asset	103	103	102	105	104	134	133	137	140	144	149	156
Goodwill	523	510	534	549	555	667	674	678	690	692	716	717
Total assets	1,010	997	1,017	1,023	1,029	1,167	1,180	1,180	1,196	1,204	1,242	1,249
Accrued liabilities	36	55	54	58	65	60	68	65	57	81	57	45
Current portion of long-term debt	8	8	9	10	10	11	9	8	9	10	11	5
Total current liabilities	82	102	103	107	115	116	124	119	115	139	117	110
Long-term debt	141	139	137	136	133	143	157	152	151	153	194	215
Lease liability, non-current	77	77	76	78	77	102	101	104	106	111	115	123
Total liabilities	342	345	345	353	358	408	421	414	414	434	459	482
Retained earnings	239	224	224	226	226	227	234	236	237	227	217	213
Total stockholders' equity	492	476	480	485	483	489	497	501	504	476	469	449
Total liabilities and equity	1,010	997	1,017	1,023	1,029	1,167	1,180	1,180	1,196	1,204	1,242	1,249
Common shares outstanding (cover page) millions of shares	15	15	15	15	15	15	15	15	15	15	15	15

Fiscal quarters (USPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	9	1*	8	8	7	9*	10	12	13	4*	5	10
Stock-based compensation	2*	2*	2	2*	2*	2*	2	2*	2*	2*	2	3*
Depreciation and amortization	4*	4*	4	5*	4*	6*	6	6*	6*	5*	6	6*
Net cash from operating activities	16*	27*	4	29*	22*	19*	(5)	35*	20*	25*	4	34*
Net cash from investing activities	(17)*	(8)*	(20)	(28)*	(6)*	(95)*	(7)	(13)*	(12)*	(5)*	(40)	(6)*
Proceeds from issuing common stock	(0)*	0*	—	—	0*	0*	—	—	—	year only	—	—
Share repurchases	—	year only	—	—	—	year only	—	—	—	year only	—	—
Dividends paid	6*	6*	—	—	7*	7*	—	—	7*	7*	—	—
Proceeds from long-term debt	0*	0*	—	—	—	year only	—	—	—	—	—	—
Repayments of long-term debt	1*	1*	1	1*	2*	0*	4	2*	2*	2*	2	0*
Net cash from financing activities	(12)*	(13)*	(4)	(20)*	(12)*	(0)*	9	(27)*	(11)*	(15)*	29	(32)*
Net change in cash	(13)*	5*	(21)	(19)*	4*	(76)*	(2)	(5)*	(3)*	4*	(7)	(4)*

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
U S Physical Therapy	25	214	34*	14.9M	—	Q2 FY26 10-QJun 30, 2026
LifeStance Health Group	226	435	100*	382.1M	—	Q2 FY26 10-QJun 30, 2026
Pennant Group	15	298	22*	34.9M	—	Q2 FY26 10-QJun 30, 2026
Omada Health	222	88	4*	61.2M	—	Q2 FY26 10-QJun 30, 2026
Talkspace	39	62	11*	165.8M	—	Q2 FY26 10-QJun 30, 2026
GeneDx Holdings	60	114	(29)*	29.8M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Privia Health Group	412	not reported	1.1*	127.7M	—	Q2 FY26 10-QJun 30, 2026
Strata Critical Medical	35	74	9.5*	89.3M	—	Q3 FY26 10-QSep 30, 2026
DocGo	25	73	(9.2)*	98.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.